Pure Global
NCT06301425

MRD Response-adapted Allo-HSCT for Adverse-risk AML

Measurable Residual Disease Response-adapted Allogeneic Hematopoietic Stem Cell Transplantation for Adverse-risk Acute Myeloid Leukemia: an Open-label, Randomized, Controlled Trial（TROPHY-AML01）
Peking University People's Hospital·ClinicalTrials.gov·otherNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Myeloid Leukemia
Drug/Device/Intervention
Intervention group
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Peking University People's Hospital
Timeline & enrollment
Phase
N/A
Start date
May 01, 2024
End date
May 01, 2028
Enrollment
178 participants
Primary outcome

Event-free survival (EFS)

Summary

This TROPHY-AML01 regimen aims to identify the effectiveness and safety of MRD
 response-adapted allo-HSCT for adverse-risk acute myeloid leukemia in an open-label,
 randomized, controlled trial.

ICD-10 classifications
Myeloid leukaemiaAcute myeloblastic leukaemia [AML]Myeloid leukaemia, unspecifiedAcute myelomonocytic leukaemiaAcute myeloid leukaemia with 11q23-abnormality
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06301425
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06301425 through Pure Global AI's free database. This phase not specified trial is sponsored by Peking University People's Hospital and is currently Not yet recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 178 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.